scholarly journals Glucose Sensing in the Subcutaneous Tissue: Attempting to Correlate the Immune Response with Continuous Glucose Monitoring Accuracy

2018 ◽  
Vol 20 (5) ◽  
pp. 321-324 ◽  
Author(s):  
Jeffrey I Joseph ◽  
Gabriella Eisler ◽  
David Diaz ◽  
Abdurizzagh Khalf ◽  
Channy Loeum ◽  
...  
2012 ◽  
Vol 6 (5) ◽  
pp. 1103-1106 ◽  
Author(s):  
Yoeri M. Luijf ◽  
Angelo Avogaro ◽  
Carsten Benesch ◽  
Daniela Bruttomesso ◽  
Claudio Cobelli ◽  
...  

2018 ◽  
Vol 15 (3) ◽  
pp. 175-184 ◽  
Author(s):  
Ramzi A Ajjan ◽  
Michael H Cummings ◽  
Peter Jennings ◽  
Lalantha Leelarathna ◽  
Gerry Rayman ◽  
...  

Continuous glucose monitoring and flash glucose monitoring technologies measure glucose in the interstitial fluid and are increasingly used in diabetes care. Their accuracy, key to effective glycaemic management, is usually measured using the mean absolute relative difference of the interstitial fluid sensor compared to reference blood glucose readings. However, mean absolute relative difference is not standardised and has limitations. This review aims to provide a consensus opinion on assessing accuracy of interstitial fluid glucose sensing technologies. Mean absolute relative difference is influenced by glucose distribution and rate of change; hence, we express caution on the reliability of comparing mean absolute relative difference data from different study systems and conditions. We also review the pitfalls associated with mean absolute relative difference at different glucose levels and explore additional ways of assessing accuracy of interstitial fluid devices. Importantly, much data indicate that current practice of assessing accuracy of different systems based on individualised mean absolute relative difference results has limitations, which have potential clinical implications. Healthcare professionals must understand the factors that influence mean absolute relative difference as a metric for accuracy and look at additional assessments, such as consensus error grid analysis, when evaluating continuous glucose monitoring and flash glucose monitoring systems in diabetes care. This in turn will ensure that management decisions based on interstitial fluid sensor data are both effective and safe.


2015 ◽  
Vol 9 (5) ◽  
pp. 1092-1102 ◽  
Author(s):  
Zeinab Mahmoudi ◽  
Mette Dencker Johansen ◽  
Hanne Holdflod Nørgaard ◽  
Steen Andersen ◽  
Ulrik Pedersen-Bjergaard ◽  
...  

2015 ◽  
Vol 19 (2) ◽  
pp. 159-166 ◽  
Author(s):  
Masaya Munekage ◽  
Tomoaki Yatabe ◽  
Masahiko Sakaguchi ◽  
Hiroyuki Kitagawa ◽  
Takahiko Tamura ◽  
...  

2019 ◽  
Vol 21 (5) ◽  
pp. 295-302 ◽  
Author(s):  
Isabelle Isa Kristin Steineck ◽  
Zeinab Mahmoudi ◽  
Ajenthen Ranjan ◽  
Signe Schmidt ◽  
John Bagterp Jørgensen ◽  
...  

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 74-LB
Author(s):  
JOI HESTER ◽  
GEORGIA M. DAVIS ◽  
FRANCISCO J. PASQUEL ◽  
MARINA RABINOVICH ◽  
NORMA POINDEXTER ◽  
...  

2005 ◽  
Vol 7 (1) ◽  
pp. 163-173 ◽  
Author(s):  
A. Mang ◽  
J. Pill ◽  
N. Gretz ◽  
B. Kränzlin ◽  
H. Buck ◽  
...  

2020 ◽  
Vol 15 (1) ◽  
pp. 167-173 ◽  
Author(s):  
Jeffrey I. Joseph

The article published by Kevin Cowart in this issue of the Journal of Diabetes Science and Technology (JDST) is a detailed overview of the clinical trial data and analysis used to demonstrate the safety and effectiveness of the Eversense continuous glucose monitoring (CGM) System for regulatory approval and clinical acceptance. The article describes the published study results for safety, accuracy, reliability, ease of insertion/removal, adverse events, and ease of diabetes patient-use for controlling their glucose levels short and long term. The author nicely compares Eversense CGM System safety and performance with the short-term subcutaneous tissue CGM systems being commercialized by Dexcom, Medtronic Diabetes, and Abbott Diabetes. This comparison may help the clinician define which type of patient with diabetes might benefit the most from the long-term implantable CGM system. The majority of studied patients describe a positive experience managing their diabetes with the Eversense CGM System and request implantation of a new sensor 90 or 180 days later.


Sign in / Sign up

Export Citation Format

Share Document